Regulus Therapeutics reported $24.23M in Cash and Equivalent for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Alnylam Pharmaceuticals ALNY:US USD 866.39M 206.83M
AstraZeneca AZN:LN USD 6.17B 1.71B
Astrazeneca AZN:US USD 6.17B 1.71B
Biogen BIIB:US USD 3.42B 256.3M
Celldex Therapeutics CLDX:US USD 29.43M 10.85M
Gilead Sciences GILD:US USD 7.63B 2.93B
GlaxoSmithKline GSK:LN GBP 3.72B 117M
Intercept Pharmaceuticals ICPT:US USD 50.52M 62.68M
Intrexon XON:US USD 4.86M 4.21M
Lexicon Pharmaceuticals LXRX:US USD 46.34M 27.51M
Ligand Pharmaceuticals LGND:US USD 211.87M 207.75M
Omeros OMER:US USD 11.01M 134.52M
Regulus Therapeutics RGLS:US USD 24.23M 4.21M
Sangamo Biosciences SGMO:US USD 100.44M 5.87M
Spectrum Pharmaceuticals SPPI:US USD 56.26M 30.74M
Takeda 4502:JP JPY 685.14B 113B
Vital Therapies VTL:US USD 106.74M 33.97M
YTE INCY:US USD 2.95B 260.8M